MX2016005686A - Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes. - Google Patents

Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.

Info

Publication number
MX2016005686A
MX2016005686A MX2016005686A MX2016005686A MX2016005686A MX 2016005686 A MX2016005686 A MX 2016005686A MX 2016005686 A MX2016005686 A MX 2016005686A MX 2016005686 A MX2016005686 A MX 2016005686A MX 2016005686 A MX2016005686 A MX 2016005686A
Authority
MX
Mexico
Prior art keywords
neutralizing antibodies
ligand binding
binding assay
competitive ligand
detecting
Prior art date
Application number
MX2016005686A
Other languages
English (en)
Inventor
Rajadhyaksha Manoj
SHYU Gary
GEORGAROS Camille
Partridge Michael
Torri Albert
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51905411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016005686(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2016005686A publication Critical patent/MX2016005686A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se refiere a un ensayo de inmunogenicidad, para detectar la presencia de anticuerpos neutralizantes contra una proteína bioterapéutica, en donde la proteína bioterapéutica ha sido administrada a un paciente que la necesita, que comprende los pasos de: (a) obtener una muestra del paciente; (b) incubar la muestra en presencia de un reactivo de captura; y (c) agregar un reactivo de detección, en donde una disminución de la señal en relación con una muestra de control, indica la presencia de un anticuerpo neutralizante contra el agente bioterapéutico.
MX2016005686A 2013-10-31 2014-10-30 Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes. MX2016005686A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898046P 2013-10-31 2013-10-31
PCT/US2014/063034 WO2015066259A1 (en) 2013-10-31 2014-10-30 Competitive ligand binding assay for detecting neutralizing antibodies

Publications (1)

Publication Number Publication Date
MX2016005686A true MX2016005686A (es) 2016-08-11

Family

ID=51905411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005686A MX2016005686A (es) 2013-10-31 2014-10-30 Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.

Country Status (12)

Country Link
US (1) US10261094B2 (es)
EP (1) EP3063543B1 (es)
JP (1) JP6756611B2 (es)
KR (1) KR102101987B1 (es)
CN (1) CN105765386B (es)
AU (1) AU2014342316B2 (es)
BR (1) BR112016009460B1 (es)
CA (1) CA2928730C (es)
IL (2) IL245188A0 (es)
MX (1) MX2016005686A (es)
RU (1) RU2701684C2 (es)
WO (1) WO2015066259A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005686A (es) 2013-10-31 2016-08-11 Regeneron Pharma Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
IL307286B2 (en) * 2018-04-11 2026-03-01 Regeneron Pharma Methods and compositions for quantifying il-33
JP7541534B2 (ja) * 2019-05-13 2024-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
CA3180569A1 (en) * 2020-05-01 2021-11-04 Regeneron Pharmaceuticals, Inc. Neutralizing antibody assay for therapeutic proteins
US20210364506A1 (en) * 2020-05-22 2021-11-25 Robert Bosch Gmbh Methods for detecting an amount of an analyte in a solution
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法
CN116930475A (zh) * 2022-03-31 2023-10-24 上海细胞治疗集团药物技术有限公司 中和抗体检测方法
CN115078733A (zh) * 2022-06-10 2022-09-20 苏州方达新药开发有限公司 检测细胞因子融合蛋白的中性抗体的方法
CN120239821A (zh) * 2022-09-23 2025-07-01 默沙东有限责任公司 中和抗体测定方法
CN115561355B (zh) * 2022-09-26 2024-04-30 重庆迪纳利医药科技有限责任公司 羧肽酶g2的中和抗体检测方法以及基于lc-ms/ms的检测系统
CN119881340B (zh) * 2025-03-26 2025-08-12 军科正源（北京）药物研究有限责任公司 检测抗HBV preS1单抗候选药物中和抗体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
FR2813606B1 (fr) 2000-09-01 2004-04-30 Inst Nat Sante Rech Med Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
WO2005017529A1 (en) 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti cd20 antibodies and uses therefor
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JP4148367B1 (ja) * 2007-08-02 2008-09-10 富山県 細胞のスクリーニング方法
ES2550158T3 (es) * 2007-08-06 2015-11-04 Chugai Seiyaku Kabushiki Kaisha Método para medir la actividad inhibidora sobre la unión ligando-receptor
WO2009045321A1 (en) * 2007-09-28 2009-04-09 Stryker Corporation Methods for detecting neutralizing antibodies for bone morphogenetic proteins
CN102387814A (zh) * 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US20120148594A1 (en) 2009-08-21 2012-06-14 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
PL2564202T3 (pl) * 2010-04-29 2016-04-29 Theradiag Sa Sposoby wykrywania przeciwciał przeciw lekowi
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013071055A1 (en) 2011-11-10 2013-05-16 Wellstat Diagnostics, Llc Assay for diabetes-associated autoantibodies
ES3066738T3 (en) * 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
MX2016005686A (es) 2013-10-31 2016-08-11 Regeneron Pharma Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.

Also Published As

Publication number Publication date
US20160252520A1 (en) 2016-09-01
RU2701684C2 (ru) 2019-09-30
KR102101987B1 (ko) 2020-04-20
RU2016121151A (ru) 2017-12-05
EP3063543B1 (en) 2020-03-11
BR112016009460B1 (pt) 2020-09-29
CA2928730A1 (en) 2015-05-07
US10261094B2 (en) 2019-04-16
RU2016121151A3 (es) 2018-07-31
EP3063543A1 (en) 2016-09-07
BR112016009460A8 (pt) 2020-05-12
CN105765386A (zh) 2016-07-13
AU2014342316A1 (en) 2016-05-19
IL269870B (en) 2020-08-31
WO2015066259A1 (en) 2015-05-07
AU2014342316B2 (en) 2019-07-25
CA2928730C (en) 2020-06-02
IL245188A0 (en) 2016-06-30
JP6756611B2 (ja) 2020-09-16
JP2016536587A (ja) 2016-11-24
KR20160070111A (ko) 2016-06-17
CN105765386B (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
HK1210831A1 (en) Compositions and methods for detecting protease activity in biological systems
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
WO2011005357A3 (en) Immunogenicity assay
WO2015095355A3 (en) Detection of an antibody against a pathogen
PH12015502470A1 (en) Human fcrn-binding modified antibodies and methods of use
EP3933406A3 (en) Antibodies to risperidone and use thereof
WO2013043933A3 (en) Cd27l antigen binding proteins
HK1223943A1 (zh) 嵌合的靶向抗原受体的单克隆抗体
WO2014031668A3 (en) Antibodies to quetiapine and use thereof
WO2011088385A3 (en) Compositions and methods for detecting cancer
WO2013165972A3 (en) Anti-hepatitis b virus antibodies and use thereof
WO2014031662A3 (en) Antibodies to olanzapine and use thereof
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
MX367105B (es) Método para la detección de infección por h. pylori.
HK1244534A1 (zh) 重组疏螺旋体蛋白及其使用方法
EP3467498A4 (en) MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY OR ANTIBODY KIT, INSOLUBLE CARRIER PARTICLE TO WHICH THE MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY IS IMMOBILIZED, AND MEASURING REAGENT AND MEASURING METHODS USED THEREOF
AR098221A1 (es) Conjugados de anticuerpo anti-efna4-fármaco
EP3508849A4 (en) ANTIBODY MEASUREMENT METHOD USING ANTI-CARRYING NON-SOLUBLE CARRIER PARTICLES ON WHICH ANTIQUE IS IMMOBILIZED BY DIFFERENT METHODS, AND REAGENT FOR ANTIBODY MEASUREMENT
EP2769994A3 (en) Ritalinic acid immunoassay
MX2012005595A (es) Proteina marcadora para diabetes de tipo 2.
HK1243953A1 (zh) 检测人dpp-4的测定法
WO2015069718A3 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration